Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GDUFA Stakeholder Deadline May Come After Negotiations Conclude

This article was originally published in The Pink Sheet Daily

Executive Summary

Generic drug user fee reauthorization talks remain on schedule and are expected to last about four months.

You may also be interested in...



FDA Generic Office Director Uhl Returns From Medical Leave

Kathleen Uhl's five-month leave for cancer treatment ends as user fee negotiations move towards formal start.

ANDA Approvals: Is FDA Productivity Boost Permanent?

Fourth consecutive month of strong results suggests generic review function is back on track.

ANDA Sponsors: Update Your FDA Contacts List

New policy allows more FDA staffers to answer certain questions about pending applications, rather than channeling them all through the regulatory project manager.

Related Content

Topics

UsernamePublicRestriction

Register

PS078801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel